Azitra Inc

Azitra Inc a preclinical biopharmaceutical company focuses on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases It is developing ATR12 a genetically modified strain of S epidermidis for treating Netherton syndrome a skin disease ATR04 a genetically modified strain of S epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor and ATR01 an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris a skin disease The company was incorporated in 2014 and is based in Branford Connecticut